Asset Details
Do you wish to reserve the book?
Prevalence and Predictors of Liver Fibrosis in People Living with Hepatitis B in Senegal
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prevalence and Predictors of Liver Fibrosis in People Living with Hepatitis B in Senegal
Do you wish to request the book?
Prevalence and Predictors of Liver Fibrosis in People Living with Hepatitis B in Senegal
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prevalence and Predictors of Liver Fibrosis in People Living with Hepatitis B in Senegal
2022
Overview
Hepatitis B virus (HBV) infection is the first cause of liver cirrhosis and cancer in West Africa. Although the exposure to additional environmental and infectious risk factors may lead to the faster progression of liver disease, few large-scale studies have evaluated the determinants of HBV-related liver fibrosis in the region. We used transient elastography to evaluate the prevalence of liver fibrosis and assessed the association between HBV markers and significant liver fibrosis in a cohort of people living with HBV in Dakar, Senegal. The prevalence of significant liver fibrosis was 12.5% (95% confidence interval [CI] 9.6%–15.9%) among 471 people with HBV mono-infection (pwHBV) and 6.4% (95% CI 2.6%–12.7%) in 110 people with HIV/HBV co-infection (pwHIV/HBV) on tenofovir-containing antiretroviral therapy (p = 0.07). An HBV viral load > 2000 IU/mL was found in 133 (28.3%) pwHBV and 5 (4.7%) pwHIV/HBV, and was associated with significant liver fibrosis (adjusted odds ratio (aOR) 1.95, 95% CI 1.04–3.66). Male participants (aOR 4.32, 95% CI 2.01–8.96) and those with elevated ALT (aOR 4.32, 95% CI 2.01–8.96) were especially at risk of having significant liver fibrosis. Our study shows that people with an HBV viral load above 2000 IU/mL have a two-fold increase in the risk of liver fibrosis and may have to be considered for antiviral therapy, independent of other disease parameters.
Publisher
MDPI AG,MDPI
Subject
/ Complications and side effects
/ elasticity imaging techniques
/ Fibrosis
/ Hepatitis B, Chronic - complications
/ Hepatitis B, Chronic - drug therapy
/ Hepatitis B, Chronic - epidemiology
/ HIV
/ HIV Infections - complications
/ HIV Infections - drug therapy
/ HIV Infections - epidemiology
/ Human immunodeficiency virus
/ Humans
/ Liver Cirrhosis - epidemiology
/ Male
/ males
/ people
/ risk
/ Senegal
